These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Shooting the messenger: RNA-targetting CRISPR-Cas systems. Zhu Y; Klompe SE; Vlot M; van der Oost J; Staals RHJ Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29748239 [TBL] [Abstract][Full Text] [Related]
6. CRISPR: development of a technology and its applications. Derry WB FEBS J; 2021 Jan; 288(2):358-359. PubMed ID: 33300275 [TBL] [Abstract][Full Text] [Related]
7. CRISPR-Cas Systems in Streptococci. Gong T; Lu M; Zhou X; Zhang A; Tang B; Chen J; Jing M; Li Y Curr Issues Mol Biol; 2019; 32():1-38. PubMed ID: 31166168 [TBL] [Abstract][Full Text] [Related]
8. Anti-CRISPR proteins targeting the CRISPR-Cas system enrich the toolkit for genetic engineering. Liu Q; Zhang H; Huang X FEBS J; 2020 Feb; 287(4):626-644. PubMed ID: 31730297 [TBL] [Abstract][Full Text] [Related]
9. Advances in Industrial Biotechnology Using CRISPR-Cas Systems. Donohoue PD; Barrangou R; May AP Trends Biotechnol; 2018 Feb; 36(2):134-146. PubMed ID: 28778606 [TBL] [Abstract][Full Text] [Related]
10. CRISPR technologies and the search for the PAM-free nuclease. Collias D; Beisel CL Nat Commun; 2021 Jan; 12(1):555. PubMed ID: 33483498 [TBL] [Abstract][Full Text] [Related]
12. CRISPR-Cas9 in genome editing: Its function and medical applications. Khadempar S; Familghadakchi S; Motlagh RA; Farahani N; Dashtiahangar M; Rezaei H; Gheibi Hayat SM J Cell Physiol; 2019 May; 234(5):5751-5761. PubMed ID: 30362544 [TBL] [Abstract][Full Text] [Related]
13. Exploration of Microbial Diversity to Discover Novel Molecular Technologies. Zhang F Keio J Med; 2019; 68(1):26. PubMed ID: 30905885 [TBL] [Abstract][Full Text] [Related]
14. CRISPR as a Diagnostic Tool. Kim S; Ji S; Koh HR Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439828 [TBL] [Abstract][Full Text] [Related]
15. CRISPR: History and perspectives to the future. Kozovska Z; Rajcaniova S; Munteanu P; Dzacovska S; Demkova L Biomed Pharmacother; 2021 Sep; 141():111917. PubMed ID: 34328110 [TBL] [Abstract][Full Text] [Related]
16. Inconclusive studies on possible CRISPR-Cas off-targets should moderate expectations about enzymes that have evolved to be non-specific. Chakraborty S J Biosci; 2018 Jun; 43(2):225-228. PubMed ID: 29872009 [No Abstract] [Full Text] [Related]
17. Type II anti-CRISPR proteins as a new tool for synthetic biology. Zhang Y; Marchisio MA RNA Biol; 2021 Aug; 18(8):1085-1098. PubMed ID: 32991234 [TBL] [Abstract][Full Text] [Related]
18. Expanding the scope of plant genome engineering with Cas12a orthologs and highly multiplexable editing systems. Zhang Y; Ren Q; Tang X; Liu S; Malzahn AA; Zhou J; Wang J; Yin D; Pan C; Yuan M; Huang L; Yang H; Zhao Y; Fang Q; Zheng X; Tian L; Cheng Y; Le Y; McCoy B; Franklin L; Selengut JD; Mount SM; Que Q; Zhang Y; Qi Y Nat Commun; 2021 Mar; 12(1):1944. PubMed ID: 33782402 [TBL] [Abstract][Full Text] [Related]
19. Engineering the Delivery System for CRISPR-Based Genome Editing. Glass Z; Lee M; Li Y; Xu Q Trends Biotechnol; 2018 Feb; 36(2):173-185. PubMed ID: 29305085 [TBL] [Abstract][Full Text] [Related]